|Corporate Address||110 Bi County Blvd. Ste. 122|
Farmingdale, NY 11735
|Description of Business||Digital biotechnology company for epigenetic-based personalized skincare|
|Type of Security Offered||ERC20-Standard Digital Tokens|
Name or Symbol of Security
EpigenCare Credits or "EPIC" Tokens
|Purchase Price of Security Offered||$0.40|
|Minimum Investment Amount (per investor) ||$400|
The Investment Offering
$0.40 per EPIC security token | 2,675,000* available for sale through this offering
*Maximum subject to adjustment for bonus tokens. See 10% Bonus below
50,000,000 security tokens total from all offerings, 60,000,000 security tokens total fixed supply
Option to Convert 5 EPIC to 1 Common Stock after 1 year
48,000,000 Common Stock currently outstanding out of 80,000,000 authorized
EPIC holders receive revenue sharing payments based on 15% and 10% of first 2 years of revenue, respectively, and 5% thereafter
Revenue sharing payments are paid based on fixed proportion of 60,000,000 EPIC
Revenue sharing is first paid at the end of a 1-year holding period, then quarterly thereafter
$400+ Acknowledgement of contribution on official EpigenCare webpage (optional)
$800+ 5% Additional Token Bonus
$2,400+ 10% Additional Token Bonus
$4,000+ 10% Additional Token Bonus + 1 Transferable First-Access Voucher for a Skincare Test ($299 value, US only)
$7,200+ 15% Additional Token Bonus + 2 Transferable First-Access Vouchers for a Skincare Test ($598 value, US only)
$10,400+ 15% Additional Token Bonus + 6 Transferable First-Access Vouchers for a Skincare Test ($1,794 value, US only)
*All perks will occur at the end of this offering. All token bonuses and vouchers will be issued separately by EpigenCare, not StartEngine.
All tokens will be delivered by EpigenCare to your Ethereum wallet address between April 16, 2018 and June 30, 2018. If you do not possess an Ethereum wallet address, you will be provided with one along with its private access key with instructions for access and safekeeping.
The 10% Bonus for StartEngine Shareholders
EpigenCare Inc. will offer 10% additional bonus tokens for all investments that are committed by StartEngine Crowdfunding Inc. shareholders (with ≥ $1,000 invested in the StartEngine Reg A+ campaign) within 24 hours of this offering going live.
StartEngine shareholders who have invested $1,000+ in the StartEngine Reg A+ campaign will receive a 10% bonus on this offering within a 24-hour window of their campaign launch date. This means you will receive a bonus for any tokens you purchase. For example, if you buy 400 EPIC Tokens at $0.40 / Token, you will receive 40 EPIC Bonus Tokens bonus, meaning you'll own 440 tokens for $160. Fractional tokens will not be distributed and token bonuses will be determined by rounding down to the nearest whole token.
This 10% Bonus is only valid for one year from the time StartEngine Crowdfunding Inc. investors receive their countersigned StartEngine Crowdfunding Inc. subscription agreement.
Irregular Use of Proceeds
The Company might incur Irregular Use of Proceeds that may include but are not limited to the following over $10,000: Vendor payments and salary made to one's self, a friend or relative; Any expense labeled "Administration Expenses" that is not strictly for administrative purposes; Any expense labeled "Travel and Entertainment"; Any expense that is for the purposes of inter-company debt or back payments. The related party, EpiGentek Group Inc., of the Company has provided a credit of line of $100,000 with 1% interest rate. As of February 15, 2018, EpiGentek has funded the Company's operating expenses in the amount of $23,032. These expenses are anticipated to be reimbursed once the Company obtains a minimum funding of $1,000,000, payable immediately (see "Use of Proceeds" section for additional information). Should the Company fail to raise this amount by December 31, 2018, the debt shall be converted to a three-year loan with the interest rate of 7%.
Most recent fiscal year-end:
Prior fiscal year-end:
Cash And Cash Equivalents
A crowdfunding investment involves risk. You should not invest any funds in this offering unless you can afford to lose your entire investment. In making an investment decision, investors must rely on their own examination of the issuer and the terms of the offering, including the merits and risks involved. These securities have not been recommended or approved by any federal or state securities commission or regulatory authority. Furthermore, these authorities have not passed upon the accuracy or adequacy of this document. The U.S. Securities and Exchange Commission does not pass upon the merits of any securities offered or the terms of the offering, nor does it pass upon the accuracy or completeness of any offering document or literature. These securities are offered under an exemption from registration; however, the U.S. Securities and Exchange Commission has not made an independent determination that these securities are exempt from registration.